

Pharmacogenomics Drives Lenalidomide Efficacy and MRD Kinetics in Mantle Cell Lymphoma after Autologous Transplantation: Results from the MCL0208 Multicenter, Phase

*Original*

Pharmacogenomics Drives Lenalidomide Efficacy and MRD Kinetics in Mantle Cell Lymphoma after Autologous Transplantation: Results from the MCL0208 Multicenter, Phase III, Randomized Clinical Trial from the Fondazione Italiana Linfomi (FIL) / Ferrero, S., Grimaldi, D., Arrigoni, E., Zaccaria, G.M., Alessandria, B., Genuardi, E., De Luca, G., Ghislieri, M., Di Rocco, A., Re, A., Stefoni, V., Cavallo, F., Boccomini, C., Balzarotti, M., Zilioli, V.R., Maria, G.d.S., Arcaini, L., Molinari, A.L., Ballerini, F., Ferreri, A.J., et al.. - In: BLOOD. - ISSN 0006-4971. - ELETTRONICO. - 136:(2020), pp. 16-17. (62th American Society of Hematology Annual Meeting ) [10.1182/blood-2020-134875].

*Availability:*

This version is available at: 11583/2993213 since: 2024-10-09T12:50:55Z

*Publisher:*

American Society of Hematology

*Published*

DOI:10.1182/blood-2020-134875

*Terms of use:*

This article is made available under terms and conditions as specified in the corresponding bibliographic description in the repository

*Publisher copyright*

(Article begins on next page)

## **Pharmacogenomics Drives Lenalidomide Efficacy and MRD Kinetics in Mantle Cell Lymphoma after Autologous Transplantation: Results from the MCL0208 Multicenter, Phase III, Randomized Clinical Trial from the Fondazione Italiana Linfomi (FIL)**

Simone Ferrero, MD,<sup>1,2</sup> Daniele Grimaldi, MD,<sup>\*,3</sup> Elena Arrigoni,<sup>\*,4</sup> Gian Maria Zaccaria, PhD,<sup>\*,3</sup>  
Beatrice Alessandria,<sup>\*,3</sup> Elisa Genuardi,<sup>\*,3</sup> Gabriele De Luca,<sup>\*,3</sup> Marco Ghislieri,<sup>\*,5</sup>  
Alice Di Rocco,<sup>\*,6</sup> Alessandro Re, MD,<sup>\*,7</sup> Vittorio Stefoni, MD PhD,<sup>\*,8</sup> Federica Cavallo,<sup>\*,1,3</sup>  
Carola Boccomini, MD,<sup>\*,9</sup> Monica Balzarotti,<sup>\*,10</sup> Vittorio Ruggero Zilioli, MD,<sup>\*,11</sup> Gomes da  
Silva Maria, MD PhD,<sup>\*,12</sup> Luca Arcaini,<sup>\*,13</sup> Anna Lia Molinari, MD,<sup>\*,14</sup> Filippo Ballerini, MD,<sup>\*,15</sup>  
Andres JM Ferreri, MD,<sup>16</sup> Benedetta Puccini,<sup>\*,17</sup> Giuseppe A. Palumbo, MD PhD,<sup>\*,18</sup>  
Sara Galimberti, MD PhD,<sup>\*,19</sup> Sergio Cortelazzo, MD,<sup>\*,20</sup> Antonello Di Paolo,<sup>\*,4</sup> Marco Ladetto, MD<sup>21</sup>

<sup>1</sup>Hematology, University of Torino and Hospital "Città della Salute e della Scienza di Torino", Torino, Italy

<sup>2</sup>Department of Molecular Biotechnologies and Health Sciences,  
Hematology Division, University of Torino, Torino, Italy

<sup>3</sup>Department of Molecular Biotechnologies and Health Sciences,  
Hematology Division, University of Torino, Torino, Italy

<sup>4</sup>Pharmacology Unit, University of Pisa, Pisa, Italy

<sup>5</sup>Department of Electronics and Telecommunications, Politecnico di Torino, Turin, Italy

<sup>6</sup>Department of Translational and Precision Medicine, Policlinico Umberto I, Roma, Italy

<sup>7</sup>ASST Spedali Civili, Brescia, Italy

<sup>8</sup>Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy

<sup>9</sup>Hematology Division 2, AOU "Città della Salute e della Scienza di Torino", Turin, Italy

<sup>10</sup>Department of Haematology, Istituto Clinico Humanitas, Rozzano, Italy

<sup>11</sup>Ospedale Metropolitan Niguarda, Milano, Italy

<sup>12</sup>Instituto Português de Oncologia - Centro de Lisboa, Departamento de Hematologia, Lisboa, Portugal

<sup>13</sup>Department of Onco-Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy

<sup>14</sup>Hematology Unit, Infermi Hospital, Rimini (FC), Italy

<sup>15</sup>Clinic of Hematology, Department of Internal Medicine  
(DiMI), IRCCS Ospedale Policlinico San Martino, Genova, Italy

<sup>16</sup>Onco-Hematology Department, Fondazione Centro San Raffaele, Milan, Italy

<sup>17</sup>Hematology Department, University of Florence and AOU Careggi, Firenze, Italy

<sup>18</sup>Department of Medical, Surgical and Advanced Technology "G.F. Ingrassia", University of Catania, Catania, Italy

<sup>19</sup>Department of Clinical and Experimental Medicine, Section of Hematology, University of Pisa, Pisa, Italy

<sup>20</sup>Clinica Humanitas/Gavazzeni, Bergamo, Italy

<sup>21</sup>Division of Hematology, A.O. SS Antonio e Biagio and Cesare Arrigo, Alessandria, Italy

*Blood* (2020) 136 (Supplement 1) : 16.


<http://doi.org/10.1182/blood-2020-134875>



**Background and Aims.** Prediction of treatment efficacy is an active and growing field of pharmacology. In the Fondazione Italiana Linfomi (FIL) MCL0208 phase III trial (NCT02354313), a 24 months lenalidomide maintenance (LM, 15 mg days 1-21 every 28 days) after high-dose immuno-chemotherapy followed by autologous transplantation (ASCT) in 300 frontline mantle cell lymphoma (MCL) patients showed substantial clinical activity in terms of Progression-Free Survival (PFS) vs observation (OBS). However, this benefit seemed not uniform across patient series. To deeper investigate the differential pattern of response to lenalidomide, a wide analysis of the host pharmacogenomics (PG) background was planned, in order to dissect whether specific germline polymorphisms of transmembrane transporters, metabolic enzymes or cell surface receptors (*ABCB1*, *ABCG2*, *VEGFA*, *FCGR2A*, *NCF4*, *GSTP1*, *CRBN*) might predict the drug efficacy. Actually, several single nucleotide polymorphisms (SNPs) of *ABCB1* exert an effect on substrate affinity of lenalidomide for the transmembrane transporter. Moreover, *VEGFA* is involved in the anti-angiogenic activity of lenalidomide and might eventually upregulate *ABCB1* expression, too. **Patients and methods.** Genotypes for SNPs were obtained through allele-specific (ASO) probes on germline DNA from peripheral blood. Minor allele frequencies (MAFs) were obtained and the Hardy-Weinberg equilibrium (HWE) was checked. Genotypes were used to infer individual haplotypes by Arlequin and Haploview softwares. Minimal residual disease (MRD) was assessed with ASO primers on either IGH or BCL-1/IGH rearrangements by RQ-PCR in bone marrow samples. *TP53* disruption was identified by NGS targeting resequencing and copy number variation analysis. Clinical-biological correlations were screened by automated machine learning methods and validated by both Kaplan-Meier at univariate level and Cox models for multivariate analysis (MV). A logistic regression was implemented to investigate correlations between polymorphisms and MRD kinetics. **Results.** 278 out of 300 patients (93%) were fully genotyped. The MAF values of the SNPs were very similar to published data and the HWE was confirmed. Most notably, *ABCB1* c.2677G>T/A(W) and *VEGFA* c.2055A>C were significantly associated to outcome and are thus described in this abstract. In the case of *ABCB1*, the three loci were in strong linkage disequilibrium ( $p < 0.001$ ). 31% of

patients were homozygous for *ABCB1* wild type alleles (GG, "WT"), 53% heterozygous (GW, "HET") and 16% polymorphic on both chromosomes (WW, "POL"). 20% were *VEGFA* WT (AA), 47% HET (AC) and 33% POL (CC). PG did not impact on induction therapy and randomization rates of this trial, as superimposable polymorphism frequencies were described between the enrolled and randomized population. Conversely, both *ABCB1* HET and POL and *VEGFA* HET/POL associated with higher MRD clearance rates vs WT after 6 months of LM (93% vs 71% and 91% vs 67%, respectively). Interestingly, the risk of MRD reappearance during LM was 86% lower for patients harboring either polymorphism vs WT (odds ratio 0.14, 95% CI 0.02-0.99;  $p < 0.05$ ). Actually, *ABCB1* HET/POL predicted for a more favorable PFS vs WT in LM (3yPFS 85% vs 69%  $p < 0.05$ , Fig.1A), as well as *VEGFA* HET/POL (3yPFS 85% vs 59%  $p < 0.01$ , Fig.1B). The two polymorphisms co-occurred in 57% of patients, being 12% *ABCB1* HET/POL only, 23% *VEGFA* HET/POL and 8% *ABCB1/VEGFA* WT. Interestingly, patients with either polymorphism had superimposable outcome to patients in whom both co-occurred (Fig.1C). Finally, MV showed that either polymorphism was protective for PFS among randomized patients (HR=0.42; 95% CI 0.20-0.85;  $p < 0.05$ ). According to this hypothesis, among the 17 *ABCB1/VEGFA* WT patients LM did not improved PFS vs OBS (Fig.1D), independently from *TP53* disruption. **Conclusions.** The first PG data on LM after ASCT in MCL suggested that: 1) *ABCB1* and *VEGFA* polymorphisms did not impact on the chemotherapeutic efficacy of FIL-MCL0208 trial; 2) both polymorphisms favored sustained MRD clearance during LM; 3) either polymorphism conferred a survival advantage during LM. Taken together, these observations hint that a variable excretion of lenalidomide through *ABCB1* (heralded by SNPs),

as well as an altered VEGFA pathway, could predict treatment efficacy. This observation might be very useful in the future to tailor lenalidomide therapy to MCL patients.



**Figure 1. Progression-Free Survival (PFS) plots according to pharmacogenomics.**

Patients randomized to LM, stratified by *ABCB1* (A), *VEGFA* (B) or by the combination of *ABCB1/VEGFA* (C) polymorphisms. Randomized series: *ABCB1* and *VEGFA* wild-type patients stratified by randomization arm (D).

## Disclosures

**Ferrero:** Servier: Speakers Bureau; **Gilead:** Research Funding, Speakers Bureau; **EUSA Pharma:** Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; **Janssen:** Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. **Boccomini:** SC Ematologia, ASOU Città della Salute e della Scienza di Torino, Turin, Italy: Current Employment. **Maria:** Roche: Consultancy, Other: travel, accommodations, expenses; **Abbvie:** Consultancy, Other: travel, accommodations, expenses; **BMS:** Consultancy; **MSD:** Consultancy; **Janssen:** Consultancy, Other: travel, accommodations, expenses; **Gilead:** Consultancy, Other: travel, accommodations, expenses, Research Funding. **Ferreri:** Gilead: Membership on an entity's Board of Directors or advisory committees, Research Funding; **Morphosys:** Research Funding; **Hutchinson:** Research Funding; **BMS:** Research Funding. **Palumbo:** Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; **Celgene:** Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; **Amgen:** Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. **Galimberti:** Novartis: Speakers Bureau; **Incyte:** Honoraria.

## OffLabel Disclosure:

Lenalidomide maintenance in mantle cell lymphoma

## Author notes

\* Asterisk with author names denotes non-ASH members.



This icon denotes a clinically relevant abstract

© 2020 by the American Society of Hematology